甲基泼尼松龙分层治疗非血缘脐血移植植入前综合征的疗效观察

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (4): 448-455.

甲基泼尼松龙分层治疗非血缘脐血移植植入前综合征的疗效观察

黄来全¹，严家炜¹，韦中玲¹，戴艳¹，苏贵平¹，蒋艺枝¹，孙自敏²，黄东平¹

¹ 皖南医学院第一附属医院弋矶山医院血液内科，芜湖 241000，安徽；² 安徽省立医院血液内科，合肥 230000，安徽

收稿日期:2017-01-23 修回日期:2017-02-06 出版日期:2017-04-26 发布日期:2017-04-26
通讯作者: 黄东平，本科，主任医师，副教授，研究方向：造血干细胞移植。 Tel：13955309713 E-mail：hdp_9713@163.com
作者简介:黄来全，男，硕士，副主任医师，研究方向：血液恶性肿瘤发病机制及造血干细胞移植。 Tel：13675531760 E-mail：13675531760@163.com
基金资助:
安徽省教育厅高校自然科学研究重点项目（KJ2017A263）；安徽省教育厅自然科学研究重大项目（KJ2016SD58）；芜湖市科技局科技惠民项目（2013hm40）

Effect of risk adjustment methylprednisolone intervention on the prognosis of pre-engraftment syndrome after unrelated cord blood transplantation

HUANG Laiquan¹, YAN Jiawei¹, WEI Zhongling ¹, DAI Yan ¹, SU Guiping ¹, JIANG Yizhi¹, SUN Zimin ², HUANG Dongping ¹

¹Department of Hematology, Yijishan Hospital of Wannan Medical College, Wuhu 241001, Anhui, China;² Department of Hematology,Affiliated Provincial Hospital,Anhui Medical University, Hefei 230001, Anhui, China

Received:2017-01-23 Revised:2017-02-06 Online:2017-04-26 Published:2017-04-26

摘要/Abstract

摘要：

目的: 研究甲基泼尼松龙（MP）分层治疗非血缘脐血造血干细胞移植（UCBT）患者植入前综合征（PES）的疗效及对UCBT结果的影响。方法: 回顾性分析自2012年11月至2015年3月于本中心接受UCBT的8例恶性血液病患者，其中单份UCBT 7例，双份UCBT 1例；急性髄系白血病4例，急性淋巴细胞白血病4例。所有患者均采用强化清髓方案行移植前预处理，其中采用分次全身照射（sTBI）7例，非sTBI 1例。PES采用MP分层治疗，预防移植物抗宿主病（GVHD）方案均采用环孢素A（CsA）联合短程霉酚酸酯（MMF），随访截止日期为2016年8月31日。结果: 8例UCBT患者移植早期均发生PES，PES累积发生率为100%。发生PES时C反应蛋白（CRP）峰值明显高于预处理阶段、PES控制后及发生Ⅱ～Ⅳ度急性GVHD（aGVHD）时的CRP水平（P<0.05），接受MP 0.5 mg·kg^-1·d^-1及MP 1 mg·kg^-1·d^-1治疗的患者两组间无统计学差异（P均＞0.05），采用MP治疗PES疗效确切。接受甲基泼尼松龙分层治疗的患者在中性粒细胞、血小板累积植入率及Ⅱ～Ⅳ度急性GVHD、Ⅲ～Ⅳ度aGVHD累积发生率上差异均无统计学意义（P均＞0.05）。8例患者UCBT后100 d均发生感染，其中细菌感染率75%，巨细胞病毒(CMV)血症发生率100%；无EB病毒(EBV)感染；接受MP 0.5 mg·kg^-1·d^-1治疗组细菌感染发生率50%，MP 1 mg·kg^-1·d^-1治疗组为100%，两组患者感染发生率上无统计学差异（P均＞0.05）。至随访截止，总生存期（OS）及总复发率均无统计学差异（P均＞0.05）。结论: UCBT后PES发生率较高，MP对UCBT后PES的治疗效果确切，且根据患者PES症状严重程度进行MP分层治疗可能减少患者感染等移植并发症，提高患者UCBT的移植疗效，延长患者生存。

关键词: 脐血干细胞移植, 植入前综合征, 甲基泼尼松龙, 回顾性研究

Abstract:

AIM: To retrospectively study the effect of risk adjustment methylprednisolone (MP) intervention on the prognosis of pre-engraftment syndrome (PES) and impacts on outcomes after unrelated cord blood transplantation (UCBT). METHODS: The data of 8 patients with acute leukemia underwent single or double UCBT from November 2012 to March 2015 were analyzed in this study, including 7 single UCBT and 1 double UCBT, half of the patients were acute lymphoblastic leukemia, and the other 4 patients were acute myeloid leukemia. All the patients were received intensified myeloablative conditioning, including 7 sTBI-based conditioning and one based on Flu. Treatment with risk adjustment methylprednisolone was given to all the patients for PES intervention. And for graft-versus-host disease (GVHD) prophylaxis, a combination of cyclosporine (CsA) and mycophenolate mofetil (MMF) was given. The cohort of patients were followed-up till to August 31, 2016. RESULTS:All the patients showed PES after UCBT and the incidence of PES was 100%. When compared the maximum C-reactive protein(CRP) level, the median value during PES was significantly higher than the serum level during conditioning therapy, after PES and the onset of II-IV acute GVHD (all P<0.05, respectively), and the result of patients received different doses of MP (0.5 mg·kg^-1·d^-1 and 1 mg·kg^-1·d^-1) showed no significant difference (P>0.05). Treatments based on different doses of MP showed a good clinical effect on PES, and there was no significant difference on transplant-related complications such as cumulative incidences of neutrophil engraftment, platelet recovery, II-IV and III-IV acute GVHD (all P>0.05, respectively). What's more, all the patients experienced infections in 100 days after UCBT. The incidence of bacterial infection was 75%, and the incidence of CMV infection was 100%. But in this study, no one experienced EBV infection after UCBT. In patients received MP 0.5 mg·kg^-1·d^-1, the incidence of bacterial infection was 50%, but it was 100% in those received MP 1 mg·kg^-1·d^-1. No significant difference was found between the 2 groups not only in infection, but also in the incidences of overall survival (OS) and relapse (P>0.05). CONCLUSION: PES seems to be common after UCBT, and MP is an effective intervention. Different doses of MP therapy based on the clinical manifestations of PES cases do not influence the results of UCBT in this cohort. Furthermore this approach can reduce patient transplant complications, improve the outcomes of UCBT and prolong the survival of patients underwent UCBT.

Key words: cord blood stem cell transplantation, pre-engraftment syndrome, methylprednisolone, retrospective studies

中图分类号:

R551

黄来全，严家炜，韦中玲，戴艳，苏贵平，蒋艺枝，孙自敏，黄东平. 甲基泼尼松龙分层治疗非血缘脐血移植植入前综合征的疗效观察[J]. 中国临床药理学与治疗学, 2017, 22(4): 448-455.

HUANG Laiquan, YAN Jiawei, WEI Zhongling, DAI Yan, SU Guiping, JIANG Yizhi, SUN Zimin, HUANG Dongping. Effect of risk adjustment methylprednisolone intervention on the prognosis of pre-engraftment syndrome after unrelated cord blood transplantation[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(4): 448-455.

参考文献

［1］Park M, Lee SH, Lee YH, et al. Pre-engraftment syndrome after unrelated cord blood transplantation: a predictor of engraftment and acute graft-versus-host disease［J］. Biol Blood Marr Trans, 2013, 19(4): 640-646.
［2］Wang X, Liu H, Sun Z，et al. Pre-engraftment syndrome after unrelated donor umbilical cord blood transplantation in patients with hematologic malignancies ［J］. Eur J Haematol, 2012, 88: 39-45.
［3］Kishi Y, Kami M, Miyakoshi S, et al. Early immune reaction after reduced-intensity cord-blood transplantation for adult patients ［J］. Transplantation, 2005, 80(1): 34-40.
［4］Patel KJ, Rice RD, Hawke R, et al. Pre-engraftment syndrome after double unit cord blood transplantation: a distinct syndrome not associated with acute Graft-Versus-Host disease［J］. Biol Blood Marr Trans, 2010, 16: 435-440.
［5］管茂静. 非血缘脐血移植后植入前综合征临床危险因素分层及干预研究和发生机制的初步探讨［D］. 安徽医科大学, 2014.
［6］ Gluckman E. Ten years of cord blood transplantation: from bench to bedside ［J］. Br J Haematol, 2009, 147(2): 192-199.
［7］ Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus Conference on Acute GVHD Grading ［J］. Bone Marr Trans, 1995, 15(6): 825-828.
［8］Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians［J］. Bone Marr Trans, 2007, 40(4): 381-387.
［9］Kanda J, Kaynar L, Kanda Y, et al. Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: Risk factors and response to treatment ［J］. Bone Marr Trans, 2013, 48(7): 926-931.
［10］ Iguchi A, Terashita Y, Sugiyama M, et al. Graft-versus-host disease (GVHD) prophylaxis by using methotrexate decreases pre-engraftment syndrome and severe acute GVHD, and accelerates engraftment after cord blood transplantation ［J］. Pediatric Trans, 2015, 20(1): 114-119.
［11］ Saito B, Hattori N, Yamamoto K, et al. Umbilical cord blood transplantation for adults using tacrolimus with two-day very-short-term methotrexate for graft-versus-host disease prophylaxis ［J］. Leuk Res, 2016, 47: 161-165.
［12］Frangoul H, Wang L, Harrell FE, et al. Preengraftment syndrome after unrelated cord blood transplant is a strong predictor of acute and chronic graft-versus-host disease［J］. Biol Blood Marr Trans, 2009, 15(11): 1485-1488.
［13］Hong KT, Kang HJ, Kim NH, et al. Peri-engraftment syndrome in allogeneic hematopoietic SCT［J］. Bone Marr Trans, 2013, 48(4): 523-528.
［14］Patel KJ, Hawke RR, Abboud M, et al. Pre-engraftment syndrome after double-unit cord blood transplantation: a distinct syndrome not associated with acute graft-versus-host disease ［J］. Biol Blood Marr Trans J Am Soc Blood Marr Trans, 2010, 16(3): 435-440.
［15］孙自敏, 刘会兰, 吴月, 等. 强化清髓不含ATG方案与清髓方案单份非血缘脐血移植治疗恶性血液病的对比观察［J］. 中华医学杂志, 2016, 96(28): 2214-2219.
［16］Lee YH, Lim YJ, Kim JY, et al. Pre-engraftment Syndrome in hematopoietic stem cell transplantation ［J］. J Korean Med Sci, 2008, 23(1): 98-103.

[1]	鲍静, 陈晓文, 夏亮, 赵雨辰, 夏瑞祥, 夏海龙. 伊沙佐米治疗多发性骨髓瘤的临床疗效和安全性分析[J]. 中国临床药理学与治疗学, 2021, 26(7): 782-786.
[2]	刘建辉, 周根鸿, 李春林, 鲍美华, 刘方怡. 生物信息学筛选骨髓增生异常综合征相关长链非编码RNA[J]. 中国临床药理学与治疗学, 2020, 25(12): 1351-1356.
[3]	常香香，韦中玲，郑幸媛，李慧敏，黄来全. 多发性骨髓瘤的治疗进展[J]. 中国临床药理学与治疗学, 2020, 25(1): 107-116.
[4]	吕晓毅, 朱娟, 翟明, 陈维信. 长效睾丸素治疗骨髓增生异常综合征21例[J]. 中国临床药理学与治疗学, 1998, 3(3): 223-224.